DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer

Information source: National Cancer Institute (NCI)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases

Intervention: anti-thymocyte globulin (Drug); cyclophosphamide (Drug); filgrastim (Drug); methotrexate (Drug); sargramostim (Drug); tacrolimus (Drug); therapeutic immune globulin (Drug); allogeneic bone marrow transplantation (Procedure); radiation therapy (Procedure)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Fox Chase Cancer Center CCOP Research Base

Official(s) and/or principal investigator(s):
Kenneth F. Mangan, MD, FACP, Study Chair, Affiliation: Fox Chase Cancer Center CCOP Research Base


RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy and radiation therapy together with bone marrow transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving bone marrow transplant from an unrelated donor together with cyclophosphamide and total-body irradiation works in treating patients with hematologic cancer.

Clinical Details

Official title: Unrelated Bone Marrow Transplantation With Cyclophosphamide and Total Body Irradiation For Hematologic Malignancies and Bone Marrow Failure States

Study design: Treatment, Open Label

Detailed description: OBJECTIVES:

- Study the curative potential of high-dose cyclophosphamide and total-body irradiation

followed by rescue with bone marrow from volunteer HLA-matched donors in patients with a variety of hematologic malignancies and bone marrow failure states.

- Study the toxic effects associated with matched unrelated bone marrow transplantation in

this patient population.

- Participate in collaborative research studies with the National Marrow Donor Program.

OUTLINE: All patients receive myeloablative therapy with high-dose cyclophosphamide and total body irradiation over 4 days; patients with severe aplastic anemia also receive antithymocyte globulin. Patients then undergo allogeneic bone marrow transplantation. Filgrastim (G-CSF) is given after transplant to accelerate engraftment. Sargramostim (GM-CSF) may be given in case of graft failure.

All patients receive graft-versus-host-disease (GVHD) prophylaxis with tacrolimus, methotrexate, and gamma globulin. Established GVHD is treated with corticosteroids and, as necessary, antithymocyte globulin.

Patients are followed at 100 days, 6 months, and 1 year after transplant, then annually thereafter.

PROJECTED ACCRUAL: A total of 10 patients per year will be accrued for this study over 5 years.


Minimum age: 17 Years. Maximum age: 60 Years. Gender(s): Both.



- One of the following hematologic malignancies/disorders:

- Acute lymphoblastic leukemia

- In second or subsequent complete remission (CR)

- In first CR with high-risk features (e. g., Philadelphia


- In first relapse and failed conventional salvage therapy

- Acute myelogenous leukemia (AML)

- In second or subsequent CR

- In early first relapse

- In full first relapse and failed conventional salvage therapy

- In first CR with high-risk features, e. g., trisomy 8 or FAB 6/7

- Standard-risk AML offered conventional-dose consolidation chemotherapy

or autologous bone marrow transplantation

- Chronic myelogenous leukemia in chronic, accelerated, or second chronic phase

- No blast crisis

- Severe aplastic anemia that has failed at least 1 course of immunosuppressive


- Paroxysmal nocturnal hemoglobinuria with high-risk features (e. g., disseminated

intravascular coagulation, thrombotic events)

- Myelodysplastic syndrome, i. e.:

- Symptomatic, transfusion-dependent refractory anemia with excess blasts

- (RAEB) or RAEB in transformation

- Secondary leukemia in CR following conventional-dose induction chemotherapy

- Unrelated marrow donor available who is 8 out of 10-, 9 out of 10-, or 10 out of

10-antigen serologically HLA-matched at A, B, C, DRb, and DQB loci by molecular typing

- No CNS malignancy



- 17 to 60

Performance status:

- Karnofsky 70-100%

Life expectancy:

- No reduction due to other serious illness


- Not specified


- Bilirubin less than 3 mg/dL

- AST/ALT no greater than twice normal


- Creatinine no greater than 2. 0 mg/dL

- Creatinine clearance greater than 60 mL/min


- Left ventricular ejection fraction at least 45%

- No severe hypertension


- DLCO, FEV_1, and FVC at least 50%


- HIV negative

- No active infection at time of transplant

- No advanced diabetes

- No significant neurologic deficit

- No active drug or substance abuse

- No emotional disorders

- Able to participate in frequent medical care for at least 1-2 years

- Willing to comply with National Marrow Donor Program policies


Biologic therapy

- See Disease Characteristics


- See Disease Characteristics

Endocrine therapy

- Not specified


- Not specified


- Not specified

Locations and Contacts

Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania 19111-2442, United States
Additional Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: August 1996
Last updated: May 23, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015